| Frank T Bryant, MD | |
|
115 E 19th St, Roswell, NM 88201-5110 | |
| (575) 622-7600 | |
| (575) 622-3856 |
| Full Name | Frank T Bryant |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 40 Years |
| Location | 115 E 19th St, Roswell, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083672489 | NPI | - | NPPES |
| 36442 | Medicaid | NM | |
| 85147 | Other | NM | NM LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 85147 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lovelace Regional Hospital - Roswell | Roswell, NM | Hospital |
| Lincoln County Medical Center | Ruidoso, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Medical Associates, Llc | 7214831114 | 291 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.
Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
Malaria is one of the world's major killers. More than 500 million people live in epidemic regions and some 2 million - mostly children - die each year. And each year, drug resistance increases in the malarial parasite, Plasmodium falciparum, and the search for new treatments becomes more desperate.
A recent study published on the preprint server bioRxiv in October 2020 reports more effective viral neutralization by bivalent anti-spike antibodies. This could promote the development of better therapeutics and vaccines.
› Verified 1 days ago
| Entity Name | Southwest Medical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164491072 PECOS PAC ID: 7214831114 Enrollment ID: O20031121000724 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.
Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
Malaria is one of the world's major killers. More than 500 million people live in epidemic regions and some 2 million - mostly children - die each year. And each year, drug resistance increases in the malarial parasite, Plasmodium falciparum, and the search for new treatments becomes more desperate.
A recent study published on the preprint server bioRxiv in October 2020 reports more effective viral neutralization by bivalent anti-spike antibodies. This could promote the development of better therapeutics and vaccines.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Frank T Bryant, MD 115 E 19th St, Roswell, NM 88201-5110 Ph: (575) 622-7600 | Frank T Bryant, MD 115 E 19th St, Roswell, NM 88201-5110 Ph: (575) 622-7600 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.
Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
Malaria is one of the world's major killers. More than 500 million people live in epidemic regions and some 2 million - mostly children - die each year. And each year, drug resistance increases in the malarial parasite, Plasmodium falciparum, and the search for new treatments becomes more desperate.
A recent study published on the preprint server bioRxiv in October 2020 reports more effective viral neutralization by bivalent anti-spike antibodies. This could promote the development of better therapeutics and vaccines.
› Verified 1 days ago
Dr. Kenneth M Yaw, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 115 E 19th St, Roswell, NM 88201 Phone: 575-622-7600 Fax: 575-622-3856 | |
Dr. Earl A Latimer Iii, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 115 E 19th St, Roswell, NM 88201 Phone: 575-622-7600 Fax: 575-622-3856 | |
Dr. James A Boss, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 115 E. 19th St., Roswell, NM 88201 Phone: 575-622-7600 Fax: 575-622-3856 | |
Dr. Zibin Zhao, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 W Country Club Rd Ste 130, Roswell, NM 88201 Phone: 575-625-2669 Fax: 575-624-4632 | |
Dr. Robert E Schwartz, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 W Country Club Rd, Suite # 130, Roswell, NM 88201 Phone: 575-625-2669 Fax: 575-624-4599 | |
Dr. Omar Nizar Osmani, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 400 N Pennsylvania Ave, Suite101, Roswell, NM 88201 Phone: 575-623-9101 Fax: 575-623-3020 |